Relationship between soluble HLA-G and HLA-A,-B,-C serum levels, and interferon-γ production after sublingual immunotherapy in patients with allergic rhinitis

Giorgio Ciprandi, Paola Continia, Daniela Fenoglio, Maria Pia Sormani, Simone Negrini, Francesco Puppo, Francesco Indiveri

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Allergic rhinitis (AR) is characterized by a T-helper (Th)-2 (Th2) polarized immune response. Soluble human leukocyte antigen (sHLA) molecules play an immunomodulatory role. Specific immunotherapy is the only causal treatment for AR and is able to shift the immune response to Th1 polarization. The aim of this study was to evaluate the relationship between sHLA-G and sHLA-A,-B,-C serum levels and interferon-γ (IFN-γ) production in AR patients with pollen allergy before and after a preseasonal course of sublingual immunotherapy (SLIT). A total of 40 AR patients with pollen allergy were enrolled and given a course of preseasonal SLIT for 3 months. Serum sHLA-G and sHLA-A,-B,-C levels were determined by enzyme-linked immunoabsorbent assay, and cell production of IFN-γ was evaluated by enzyme-linked immunoabsorbent spot assay at baseline and 3 months after the end of the SLIT course. There was a significant relationship between sHLA-G serum level change and IFN-γ increase as well as between sHLA-A,-B,-C level change and IFN-γ increase after SLIT. The present study provides the first published evidence that the reduction of sHLA molecules serum levels and the increased IFN-γ production after SLIT in AR patients with pollen allergy are significantly related phenomena.

Original languageEnglish
Pages (from-to)409-413
Number of pages5
JournalHuman Immunology
Volume69
Issue number7
DOIs
Publication statusPublished - Jul 2008

Fingerprint

Sublingual Immunotherapy
HLA-G Antigens
HLA-A Antigens
HLA-B Antigens
HLA Antigens
Interferons
Serum
Seasonal Allergic Rhinitis
Allergic Rhinitis
Enzymes
Immunotherapy

Keywords

  • Allergic rhinitis
  • IFN-γ sublingual immunotherapy
  • Pollens
  • sHLA-A,-B,-C
  • sHLA-G

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Relationship between soluble HLA-G and HLA-A,-B,-C serum levels, and interferon-γ production after sublingual immunotherapy in patients with allergic rhinitis. / Ciprandi, Giorgio; Continia, Paola; Fenoglio, Daniela; Sormani, Maria Pia; Negrini, Simone; Puppo, Francesco; Indiveri, Francesco.

In: Human Immunology, Vol. 69, No. 7, 07.2008, p. 409-413.

Research output: Contribution to journalArticle

Ciprandi, Giorgio ; Continia, Paola ; Fenoglio, Daniela ; Sormani, Maria Pia ; Negrini, Simone ; Puppo, Francesco ; Indiveri, Francesco. / Relationship between soluble HLA-G and HLA-A,-B,-C serum levels, and interferon-γ production after sublingual immunotherapy in patients with allergic rhinitis. In: Human Immunology. 2008 ; Vol. 69, No. 7. pp. 409-413.
@article{267e5e6f9630491ebdc5c51831ed53a3,
title = "Relationship between soluble HLA-G and HLA-A,-B,-C serum levels, and interferon-γ production after sublingual immunotherapy in patients with allergic rhinitis",
abstract = "Allergic rhinitis (AR) is characterized by a T-helper (Th)-2 (Th2) polarized immune response. Soluble human leukocyte antigen (sHLA) molecules play an immunomodulatory role. Specific immunotherapy is the only causal treatment for AR and is able to shift the immune response to Th1 polarization. The aim of this study was to evaluate the relationship between sHLA-G and sHLA-A,-B,-C serum levels and interferon-γ (IFN-γ) production in AR patients with pollen allergy before and after a preseasonal course of sublingual immunotherapy (SLIT). A total of 40 AR patients with pollen allergy were enrolled and given a course of preseasonal SLIT for 3 months. Serum sHLA-G and sHLA-A,-B,-C levels were determined by enzyme-linked immunoabsorbent assay, and cell production of IFN-γ was evaluated by enzyme-linked immunoabsorbent spot assay at baseline and 3 months after the end of the SLIT course. There was a significant relationship between sHLA-G serum level change and IFN-γ increase as well as between sHLA-A,-B,-C level change and IFN-γ increase after SLIT. The present study provides the first published evidence that the reduction of sHLA molecules serum levels and the increased IFN-γ production after SLIT in AR patients with pollen allergy are significantly related phenomena.",
keywords = "Allergic rhinitis, IFN-γ sublingual immunotherapy, Pollens, sHLA-A,-B,-C, sHLA-G",
author = "Giorgio Ciprandi and Paola Continia and Daniela Fenoglio and Sormani, {Maria Pia} and Simone Negrini and Francesco Puppo and Francesco Indiveri",
year = "2008",
month = "7",
doi = "10.1016/j.humimm.2008.05.009",
language = "English",
volume = "69",
pages = "409--413",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Relationship between soluble HLA-G and HLA-A,-B,-C serum levels, and interferon-γ production after sublingual immunotherapy in patients with allergic rhinitis

AU - Ciprandi, Giorgio

AU - Continia, Paola

AU - Fenoglio, Daniela

AU - Sormani, Maria Pia

AU - Negrini, Simone

AU - Puppo, Francesco

AU - Indiveri, Francesco

PY - 2008/7

Y1 - 2008/7

N2 - Allergic rhinitis (AR) is characterized by a T-helper (Th)-2 (Th2) polarized immune response. Soluble human leukocyte antigen (sHLA) molecules play an immunomodulatory role. Specific immunotherapy is the only causal treatment for AR and is able to shift the immune response to Th1 polarization. The aim of this study was to evaluate the relationship between sHLA-G and sHLA-A,-B,-C serum levels and interferon-γ (IFN-γ) production in AR patients with pollen allergy before and after a preseasonal course of sublingual immunotherapy (SLIT). A total of 40 AR patients with pollen allergy were enrolled and given a course of preseasonal SLIT for 3 months. Serum sHLA-G and sHLA-A,-B,-C levels were determined by enzyme-linked immunoabsorbent assay, and cell production of IFN-γ was evaluated by enzyme-linked immunoabsorbent spot assay at baseline and 3 months after the end of the SLIT course. There was a significant relationship between sHLA-G serum level change and IFN-γ increase as well as between sHLA-A,-B,-C level change and IFN-γ increase after SLIT. The present study provides the first published evidence that the reduction of sHLA molecules serum levels and the increased IFN-γ production after SLIT in AR patients with pollen allergy are significantly related phenomena.

AB - Allergic rhinitis (AR) is characterized by a T-helper (Th)-2 (Th2) polarized immune response. Soluble human leukocyte antigen (sHLA) molecules play an immunomodulatory role. Specific immunotherapy is the only causal treatment for AR and is able to shift the immune response to Th1 polarization. The aim of this study was to evaluate the relationship between sHLA-G and sHLA-A,-B,-C serum levels and interferon-γ (IFN-γ) production in AR patients with pollen allergy before and after a preseasonal course of sublingual immunotherapy (SLIT). A total of 40 AR patients with pollen allergy were enrolled and given a course of preseasonal SLIT for 3 months. Serum sHLA-G and sHLA-A,-B,-C levels were determined by enzyme-linked immunoabsorbent assay, and cell production of IFN-γ was evaluated by enzyme-linked immunoabsorbent spot assay at baseline and 3 months after the end of the SLIT course. There was a significant relationship between sHLA-G serum level change and IFN-γ increase as well as between sHLA-A,-B,-C level change and IFN-γ increase after SLIT. The present study provides the first published evidence that the reduction of sHLA molecules serum levels and the increased IFN-γ production after SLIT in AR patients with pollen allergy are significantly related phenomena.

KW - Allergic rhinitis

KW - IFN-γ sublingual immunotherapy

KW - Pollens

KW - sHLA-A,-B,-C

KW - sHLA-G

UR - http://www.scopus.com/inward/record.url?scp=51749119199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51749119199&partnerID=8YFLogxK

U2 - 10.1016/j.humimm.2008.05.009

DO - 10.1016/j.humimm.2008.05.009

M3 - Article

VL - 69

SP - 409

EP - 413

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

IS - 7

ER -